



ATTORNEY DOCKET NOS. LU61035-1, LU61036, LU61037, LU61038, LU61039, LU61040, LU61040D1			
Form PTO-1595 U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office			
RECORDATION FORM COVER SHEET PATENTS ONLY			
<u>CERTIFICATION OF FACSIMILE TRANSMISSION</u>			
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office Assignment Branch at (703) 306-5995 on <u>November 5, 2004</u> by <u>Audrey A. Boyd</u>			
			
Commissioner of Patents. Please record the attached original document or copy thereof.			
1. Name of conveying party(ies) Sanofi-Aventis, formerly known as Sanofi Synthelabo 174, avenue de France 75013 Paris, France Additional names of conveying party(ies) attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	2. Name and address of receiving party(ies) Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford, Middlesex, England Additional name(s) and addresses attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no		
3. Description of the interest conveyed: <input checked="" type="checkbox"/> Assignment, please record and return <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other Execution date of Assignment: <u>1 September 2004</u>			
4. Application number(s) or patent number(s). Additional sheets attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> A. Patent Application No.(s) 10/881,250; 10/492,102; 10/169,510 </td> <td style="width: 50%; border: none;"> B. Patent No.(s) 6,186,980; 6,585,702; 5,855,839; 6,033,387 </td> </tr> </table> If this document is being filed together with a new application, the execution date of the application is		A. Patent Application No.(s) 10/881,250; 10/492,102; 10/169,510	B. Patent No.(s) 6,186,980; 6,585,702; 5,855,839; 6,033,387
A. Patent Application No.(s) 10/881,250; 10/492,102; 10/169,510	B. Patent No.(s) 6,186,980; 6,585,702; 5,855,839; 6,033,387		
5. Name and address of party to whom correspondence concerning documents should be mailed: Kathryn L. Sieburth GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Fax: (610) 270-5090	6. Total number of applications and patents involved <u>7</u> . 7. Total Fee (37 C.F.R. 3.41) <u>\$280.00</u> 8. Please charge this fee to deposit account No. <u>19-2570</u> . The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 19-2570.		
DO NOT USE THIS SPACE			
9. Statement and Signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>			
<u>Kathryn L. Sieburth</u> Name of Person Signing	 Signature	<u>November 5, 2004</u> Date	
Total number of pages including cover sheet, attachments and document: <u>18</u>			

N:\k\cases\lu61035\Record Assignment Cover Sheet.doc

CH \$280.00 192570 10881250

Non Irish Patent Assg Agreement (closing version)

Non-Irish Patent Assignment Agreement

This Patent Assignment Agreement (the "Agreement") is made on September 1, 2004 (the "Effective Date"), by and between Sanofi-Aventis, a French corporation with its principal place of business located at 174, avenue de France, 75013 Paris, France and formerly known as Sanofi-Synthelabo (the "Assignor") and Glaxo Group Limited, a corporation organised and existing under the laws of England and Wales with its principal offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, England (the "Assignee"). The Assignor and the Assignee are individually referred to as a "Party" and collectively as the "Parties".

Unless otherwise indicated, capitalized terms used herein shall have the meaning set forth in Article 1 hereof.

WITNESSETH

NOW, THEREFORE, in consideration of the mutual agreements and undertakings contained herein, the Parties, intending to be legally bound, hereby agree as follows:

ARTICLE 1

For purposes of this Agreement, capitalized terms used herein shall have the meanings set forth below :

- 1.1 "Affiliate" or "Affiliates" shall mean as to any Person, any other Person which, directly or indirectly, controls, is controlled by, or is under common control with, such Person. For the purpose of this definition, "control" means the possession of the power to direct or cause the direction of management and policies of such individual, corporation,

JP 
PATENT

REEL: 015341 FRAME: 0424

Non Irish Patent Assg Agreement (closing version)

partnership, association, trust or other legal entity or organization, whether through direct or indirect ownership of voting securities or otherwise.

- 1.2 "Patents" shall mean the issued patents and patent applications, together with all reissues, renewals, divisions, continuations, continuations-in-part, national phase applications, substitutions, reexaminations, restorations, patent term extensions and/or supplementary protection certificates listed in Annex 1 hereto.
- 1.3 The following additional terms are terms that are defined in other Sections of this Agreement, as specifically indicated below :
- "Agreement" shall have the meaning set forth in the Preamble;
 - "Assignee" shall have the meaning set forth in the Preamble;
 - "Assignor" shall have the meaning set forth in the Preamble;
 - "Party" or "Parties" shall have the meaning set forth in the Preamble;

ARTICLE 2

The Assignor hereby transfers and assigns to the Assignee, and its respective successors and assigns, all right, title and interest it owns to and in the Patents, together with all rights and powers arising or accrued therefrom including, but not limited to, the right to sue for past and future damages and other remedies in respect of any infringement of such rights or other acts within the scope of the claims of any published specification of the Patents and the right to apply for, prosecute and obtain patents throughout the world in respect of inventions claimed in the Patents including the right to claim priority therefrom. The Assignee hereby accepts the foregoing transfer and assignment.

ARTICLE 3

The Assignor shall execute and deliver all instruments, evidence or authorizations as may be required to effect or to formalize the transfer of the Patents. If, for whatever reason, the transfer of the Patents has not become effective, in full or in part, by the signing of this Agreement, each Party will promptly do whatever it is necessary for that Party to do (and the other Party shall cooperate with it) in order to fully effectuate the transfer to the Assignee of the Patents. The Assignor hereby covenants and agrees that it will communicate to the Assignee any facts known to it with respect to the Patents. Without prejudice to Article 5, the Assignor shall perform its execution and delivery obligations under this Article 3 at its own cost.

35 CB

Non Irish Patent Assg Agreement (closing version)

ARTICLE 4

The Assignor hereby represents and warrants that, at the date hereof, the rights to the Patents are free from any charges or other restrictions and the Assignor is fully entitled and authorized to transfer the ownership of all rights to the Patents to the Assignee.

ARTICLE 5

As of the date hereof, all costs due and payable after that date in connection with the registration, maintenance and prosecution of the Patents shall be borne by the Assignee. In addition, all costs due or payable in connection with this Agreement, in particular its registration ("*enregistrement fiscal*") and the registration of the assignment of the Patents to the competent multi national or national offices shall be borne by the Assignee.

ARTICLE 6

This Agreement can not be terminated, rescinded or annulled.

ARTICLE 7

ARTICLE 8

- 8.1 This Agreement may only be amended, supplemented or modified and any provision hereof may only be waived, pursuant to a written instrument making specific reference to this Agreement and executed by duly authorized representatives of the Parties.
- 8.2 All notices and other communications under this Agreement shall be in writing and in English language and shall be deemed to have been duly given when delivered in person or upon confirmation of receipt when transmitted by facsimile transmission or on receipt

Non Irish Patent Assg Agreement (closing version)

after dispatch by registered or certified mail, postage prepaid, addressed as follows (or at such other address as the Party to whom notice is to be given has furnished in writing to the other Party):

If to Assignor:

Sanofi-Aventis
174, avenue de France
75013 Paris
France
Attention: General Counsel
Telephone: + 33 (0) 1 53 77 42 30
Facsimile: + 33 (0) 1 53 77 40 85

If to Assignee:

Glaxo Group Limited
c/o GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex
England
Attention: General Counsel
Telephone: +44 (0)208 047 5000
Facsimile: +44 (0)208 047 6939

- 8.3 The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, each of which shall remain in full force and effect; provided, however, that the Parties shall substitute any invalid or unenforceable provision by a valid and enforceable provision which maintains, to the fullest extent possible, the respective interests of the Parties as established by the present terms and conditions of the Agreement.
- 8.4 This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. Nothing in this Agreement shall create or be deemed to create any third party beneficiary rights in any individual, corporation, partnership, association, trust or other legal entity or organization not Party to this Agreement. No assignment of this Agreement or of any rights or obligations hereunder may be made by either Party without the prior written consent of the other Party and any attempted assignment without such required consent shall be null and void.
- 8.5 This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument.

Non Irish Patent Assg Agreement (closing version)

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorised officers in two (2) counterparts as of the day first written above.

SANOFI-AVENTIS

GLAXO GROUP LIMITED



By: _____
Name: Jérémy Fauriol
Title: Legal Affairs Operations Director

By: Myf
Name: JANE FRY
Title: VP LEGAL OPERATIONS

By: G. Boisson
Name: Boisson Gilles
Title: Authorized Signatory

NEX 1

SF CB

Non Irish Patent Assg Agreement (closing version)

IVD050103

Titre officiel:

Procédé de synthèse organique d'oligosaccharides constituant des fragments de mucopolysaccharides acides ou correspondant à des muco-oligosaccharides acides naturels. Préparation de dérivés de ces oligosaccharides.

Non Irish Patent Assg Agreement (closing version)

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

US / CIP	14-JAN-1983 457 931			Abandonné 21-JAN-1985	
US / CNT	26-OCT-1987 07/115593		04-AVR-1989 4818816	Date d'expiration 19-AOU-2003	19-AOU-2003

JP
Cob

Non Irish Patent Assg Agreement (closing version)

SSL0140

Titre officiel : Composition de fondaparinux sodique de haute pureté, un procédé de préparation de cette composition et compositions pharmaceutiques la contenant comme principe actif (Titre PCT)

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	----------------------------

US / CIP	30-JUN-2004 10/881250			Dépôt 30-JUN-2004	27-FEV-2023
----------	--------------------------	--	--	----------------------	-------------

Non Irish Patent Assg Agreement (closing version)

SSL0075T

Titre officiel :

USE OF SPECIFIC DOSE OF ORG 31540 / SR 90107A FOR THE TREATMENT OF ACS.

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

Non Irish Patent Assg Agreement (closing version)

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

US / PCT	07-NOV-2002 10/492102			Dépôt 07-NOV-2002	07-NOV-2022
----------	--------------------------	--	--	----------------------	-------------

JF CS

Non Irish Patent Assg Agreement (closing version)

IVD050103B

Titre officiel :

PROCEDE DE SYNTHESE ORGANIQUE D'OLIGOSACCHARIDES RENFERMANT DES
MOTIFS GALACTOSAMINE-ACIDE URONIQUE, NOUVEAUX OLIGOSACCHARIDES
OBTENUS ET LEURS APPLICATIONS BIOLOGIQUES.

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

US / CNT	21-AVR-1986 06/856865		24-JUL-1990 494363	Date d'expiration 19-AOU-2003	24-JUL-2007
US / PCT	27-OCT-1983 06-624 628			Abandonné 21-AVR-1986	

JP 

Non Irish Patent Assg Agreement (closing version)

IVD001184T

Titre officiel : Dispositif d'injection à usage unique.

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

JP GB

Non Irish Patent Assg Agreement (closing version)

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

US / BN	08-FEV-2000 09/499645		13-FEV-2001 6186910	Délivré 13-FEV-2001	08-FEV-2020
---------	--------------------------	--	------------------------	------------------------	-------------

JF WB

Non Irish Patent Assg Agreement (closing version)

IVD001185T

Titre officiel : Dispositif d'injection à usage unique

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	------------------------

US / BN	08-FEV-2000 09/499644		01-JUL-2003 6585702	Délivré 01-JUL-2003	08-FEV-2020
---------	--------------------------	--	------------------------	------------------------	-------------

Non Irish Patent Assg Agreement (closing version)

IVD001160

Titre officiel : DISPOSITIF D'INJECTION D'UNE DOSE DE LIQUIDE NOTAMMENT MEDICAMENTEUX

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	----------------------------

US / PCT	05-JAN-2001 10/169510	17-JUN-2004 2004-0116874		Publication 17-JUN-2004	05-JAN-2021
----------	--------------------------	-----------------------------	--	----------------------------	-------------

JP CAB

Non Irish Patent Assg Agreement (closing version)

IVD060136T

Titre officiel :PROCEDE DE FABRICATION D'UN DISPOSITIF D'INJECTION DU TYPE PRE-REMPLI
RENFERMANT UNE DOSE DE LIQUIDE A INJECTER, ET DISPOSITIF D'INJECTION
REALISE.

<i>Pays / Type et indice</i>	<i>Date et N° de Dépôt</i>	<i>Date et N° de Publication</i>	<i>Date et N° de Délivrance</i>	<i>Situation Proc. et Date</i>	<i>Date Expiration</i>
----------------------------------	--------------------------------	--------------------------------------	-------------------------------------	------------------------------------	----------------------------

US / BN	29-AVR-1998 08/638832		05-JAN-1999 5855838	Délivré 05-JAN-1999	29-AVR-2016
US / DIV	20-OCT-1998 09/175369		07-MAR-2000 603338	Délivré 07-MAR-2000	29-AVR-2016

JF WB